PepGen delays study for Duchenne drug as it awaits safety data from another trialnews2025-03-04T16:38:01+00:00March 4th, 2025|Endpoints News|
Swiss biotech ends Phase 2 study in Alzheimer’s shortly after Lilly and Biogen did the samenews2025-03-04T16:01:49+00:00March 4th, 2025|Endpoints News|
NIH-backed research tries to use stem cells to restore the eye’s outer layernews2025-03-04T10:00:49+00:00March 4th, 2025|Endpoints News|
GSK, Amgen and AstraZeneca tout Phase 3 data in inflammatory nasal condition news2025-03-03T20:56:47+00:00March 3rd, 2025|Endpoints News|
Pliant calls it quits on Phase 2b IPF studynews2025-03-03T20:21:10+00:00March 3rd, 2025|Endpoints News|
Biohaven’s ion channel drug fails pivotal bipolar mania studynews2025-03-03T18:19:38+00:00March 3rd, 2025|Endpoints News|
Protagonist, Takeda’s profit sharing deal under spotlight after Phase 3 blood disorder trial winnews2025-03-03T16:28:08+00:00March 3rd, 2025|Endpoints News|
Novartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfrontnews2025-03-03T15:57:41+00:00March 3rd, 2025|Endpoints News|
After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps anothernews2025-03-03T13:16:26+00:00March 3rd, 2025|Endpoints News|
Lexicon plots Phase 3 trial for diabetic pain drug despite mid-stage flopnews2025-03-03T12:00:24+00:00March 3rd, 2025|Endpoints News|
